Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

Overview of attention for article published in Frontiers in oncology, March 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 29 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,290 followers.

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. by Urbani F, Ferraresi V, Capone I, Macchia I, Palermo B…

27 Mar 2020

Reply Repost Favourite

New article: Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. https://t.co/T1gFzUGn7S #melanoma #oncology

27 Mar 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.